Remove Botox Remove Clinical Trials Remove Cosmetics Remove Life Science
article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials.

Botox 98
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 AbbVie also presented real-world data on the role of Botox in combination with CGRP mAbs for Chronic Migraine prevention. percent on a reported basis, or 29.6

Botox 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

percent increase since 2021, predominantly due to Botox sales for therapeutic uses. 2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. Botox was first approved by the FDA in 1989 for blepharospasms and strabismus in adults.

Sales 98